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The South African (SA) healthcare system has to deal with the largest 
HIV burden in the world, one of the highest incidences of TB, and 
a very high prevalence of smoking-related diseases.[1] In fact, there 
is currently renewed interest in what has been termed the ‘colliding 
epidemics’ of HIV, tobacco smoking and TB.[1] 
Two recent studies from SA showed similar changes in the pre-
dominant tissue type of lung cancer to that observed in other 
parts of the world, with adenocarcinoma being the most common 
form.[2,3] Despite the very high background prevalence of HIV and 
smoking-related diseases in sub-Saharan Africa, and the fact the lung 
cancer has become the most common non-AIDS-defining cancer 
among HIV-positive individuals on antiretroviral (ARV) therapy, 
surprisingly little is known about the presentation of lung cancer in 
HIV-infected individuals in SA.[4] Therefore, our objective was to 
compare HIV-positive and HIV-negative lung cancer patients with 
regard to demographics, cell type, performance status and umour 
node metastasis (TNM) staging at initial presentation.
Methods
We prospectively identified all cases of primary lung cancer presen-
ted at our weekly combined multidisciplinary chest oncology meeting 
from August 2013 to September 2015. Tygerberg Hospital is a 1 380-bed 
tertiary facility in Cape Town, SA. It is one of two referral centres in the 
city and renders a tertiary service to a population of about 1.5 million, of 
whom 5.2% (95% confidence interval (CI) 3.4 - 7.8%) are currently HIV-
infected. This is considerably lower than the national average of 12.2%.[5] 
We collected data on all patients with a known HIV status who 
had a tissue diagnosis of primary lung cancer and who underwent 
a staging computed tomography (CT) scan. Routine demographic 
and clinical data were collected, including the smoking status (to 
qualify as a smoker a patient had to have smoked at least 10 pack-
years per lifetime) and performance status according to the Eastern 
Cooperative Oncology Group (ECOG). 
All patients were advised and counselled to undergo HIV testing, but 
the test was only performed on those who provided written informed 
consent. The CD4 count value recorded closest to time of lung cancer 
diagnosis was documented in all HIV-positive patients. 
All patients had access to positron emission tomography-CT, 
bronchoscopy with endobronchial ultrasound, guided transbronchial 
needle aspiration with rapid onsite evaluation, transthoracic image-
guided biopsy (ultrasound or CT) and related diagnostic techniques 
that were performed at the discretion of the treating physicians as 
per standard operating procedures. A combined panel of at least a 
pulmonologist, thoracic radiologist, thoracic surgeon, specialist onco-
logist and pathologist staged all patients as per the 2009 International 
Association for the Study of Lung Cancer TNM staging system. 
Chi-square or Fisher’s exact tests (where indicated) were performed 
on dichotomous categorical variables, and t-testing on continuous 
data. 
Results
During the 2-year period, 467 of 609 (76.7%) patients with lung 
cancer consented to an HIV test or were known to be HIV-
positive at presentation. In total, 44 of 467 (9.4%) were HIV-positive 
(Table 1). The CD4 count of HIV-positive patients ranged from 9 to 
790 cells/ mL (mean 385 cells/mL). 
HIV-positive patients (mean age 54.1 (standard deviation (SD) 
8.4) years) were younger than HIV-negative patients (60.5 (10.0) 
years, p<0.001), with no significant difference in gender distribution 
or smoking prevalence (Table 1). Overall, adenocarcinoma was the 
most frequent form of lung cancer (48.9%), followed by squamous 
cell carcinoma (29.7%). In HIV-positive patients, however, squamous 
cell carcinoma was more common than adenocarcinoma (43.2% v. 
30.1%, p=0.07). 
Fifty-five of the 532 patients (10.3%) with non-small-cell lung 
cancer (NSCLC) were staged as early stage disease (up to stage IIIA). 
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Not a single HIV-positive patient had early 
stage lung cancer, compared with 38 of 
369 confirmed HIV-negative patients with 
NSCLC (0% v. 10.3%, p=0.02). 
HIV-positive patients were also more 
likely to have a poor performance status 
(ECOG 3 and 4) at presentation (47.7% v. 
29.4%, p=0.02). 
Discussion
In this prospective, observational study in 
patients with lung cancer, we found that 
HIV-positive patients were younger, more 
likely to have squamous cell carcinoma 
and significantly more likely to have 
a poor ECOG performance status of ≥3 
at presentation. Moreover, in the case of 
NSCLC, they were significantly less likely to 
have early stage lung cancer at presentation 
when compared with HIV-negative patients. 
Although lung cancer is currently the 
most common non-AIDS-defining cancer 
among HIV-positive individuals, the exact 
role of the virus in the pathogenesis of 
lung cancer remains uncertain.[4] It has 
been postulated that HIV may have a 
direct oncogenic role.[6] Some experimental 
data suggest that the HIV trans-activator 
of transcription (tat) gene product may 
modu late expression of growth-related 
genes. Other potential mechanisms include 
accelerated lung damage associated with 
HIV-related infections and an increase 
in susceptibility to tobacco carcinogens 
through genomic instability.[7]
Sigel et al.[4] analysed data from large 
US registries to calculate incidence rates of 
lung cancer in order to determine incidence 
rate ratios (IRRs), adjusting for age, sex, 
race/ethnicity, smoking prevalence, 
previous bacterial pneumonia and chronic 
obstructive pulmonary disease. The inci-
dence rate of lung cancer in HIV-positive 
patients was 204 v. 119 cases per 100 000 
person-years in uninfected patients, with 
an IRR of 1.7 (95% CI 1.5 - 1.9), arguably 
providing the strongest epidemiological 
evidence to date in favour of HIV infection 
being viewed as an independent risk factor 
for lung cancer.[4] 
In an earlier study, also performed on 
large US registries, Shiels et al.[7] found that 
the proportion of person-time contributed 
by older persons was far smaller in the 
AIDS population (1.5%) than in the general 
popu lation (12.5%). As a result, the ages 
at diagnosis for most types of cancer were 
~20  years younger among persons with 
AIDS. However, after adjustment for differ-
ences in the populations at risk, the median 
ages at diagnosis in the AIDS and general 
populations did not differ for most types of 
cancer, with the exceptions of lung (median 
50 v. 54 years) and anal cancer (median 42 
v. 45 years).[6] 
Although earlier reports have suggested 
that that a higher prevalence of smoking 
may be to blame for the increased incidence 
of lung cancer in HIV-positive individuals, 
there are currently very few data to support 
this.[4] We found no difference in smoking 
status between HIV-positive and negative 
participants.
We observed statistically significant  and 
clinically relevant differences between 
HIV- positive and HIV-negative patients 
with regard to their performance status 
and stage at presentation. All patients with 
NSCLC presented with advanced cancer, 
and approximately half had a poor ECOG 
performance status of ≥3, suggesting that the 
HIV infection adversely affected the progno-
sis of lung cancer. 
Contrary to most published series, we 
observed a trend towards squamous cell 
carcinoma as the most common tissue 
type in HIV-positive patients. Unlike anal 
cancer, where an identifiable infection such 
as human papillomavirus is involved in 
carcinogenesis, no co-infective contributor 
has been identified in lung cancer, making 
this observation difficult to elucidate.[6] Our 
data also confirmed previous observations 
that the degree of immunosuppression (as 
judged by viral load or CD4 count) seems to 
have little or no impact on the risk for lung 
cancer.[4,6] 
A limitation of our study is the fact that 
we did not specifically document socio-
economic status, level of education and 
Table 1. Demographics, cell types, stage and performance status for all lung cancer 
patients (n=610)
All
(N=610)*
HIV-negative 
(n=425)
HIV-positive
(n=44) p-value†
Demographics 
Age (years), mean (SD) 59.9 (10.1) 60.5 (10.0) 54.1 (8.4) <0.001
Gender (male), n (%) 372 (61.0) 252 (59.3) 29 (65.9) 0.42
Smokers, n (%) 557 (91.3) 389 (91.5) 40 (90.9) 1
 CD4 count (cells/mm3), mean 
(SD)
- - 385 (207) -
AIDS, n (%) 9 (1.5) 0 (0) 9 (20.5) -
Cell type, n (%)
NSCLC 
Adenocarcinoma 298 (48.9) 210 (49.4) 17 (38.7) 0.21
Squamous cell carcinoma 181 (29.7) 128 (30.1) 19 (43.2) 0.07
Poorly differentiated 28 (4.6) 18 (4.2) 2 (4.5) 1
Other 25 (4.1) 13 (3.1) 2 (4.5) 0.64
SCLC 78 (12.8) 56 (13.2) 4 (9.1) 0.64
Stage, n (%)
NSCLC
I 7 (1.3) 6 (1.6) 0 (0)
II 15 (2.8) 9 (2.4) 0 (0)
IIIA 33 (6.2) 23 (6.2) 0 (0)
IIIB 115 (21.6) 85 (23) 8 (80)
IV 362 (59.3) 246 (66.7) 32 (20) 0.02‡
SCLC 
Limited 10 (12.8) 6 (10.7) 1 (25)
Extensive 68 (87.2) 50 (89.3) 3 (75) -
ECOG performance status
0 - 2 411 (67.4) 300 (70.6) 23 (52.3)
3 - 4 199 (32.6) 125 (29.4) 21 (47.7) 0.02
SCLC = small-cell lung cancer.
*HIV status was unknown in 141 patients.    
† HIV positive v. negative.       
‡ Stages I-IIIA v. stages IIIB-IV NSCLC.
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substance abuse, all of which may be viewed as potential confounders 
that may have influenced the perceived late presentation and poor 
prognosis of the HIV-positive cohort. 
Conclusion
We found HIV-positive lung cancer patients were younger, 
significantly more likely to have a poor ECOG performance status 
of ≥3 at presentation and significantly less likely to have early 
stage lung cancer when compared with HIV-negative patients. The 
numbers of HIV-positive patients with lung cancer will most likely 
rise considerably over the next 2 decades owing to improved survival 
of patients on combination ARV therapy, resulting in an aging HIV-
positive population with a relatively higher risk for lung cancer. This 
highlights the importance of further research on lung cancer in HIV, 
especially in the setting of ‘colliding epidemics’. 
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